Etcamah (camizestrant)

Where it stands

Etcamah (camizestrant), from AstraZeneca AB, is authorised in the EU for breast neoplasms. The CHMP adopted a positive opinion on 21 May 2026, and the European Commission decision followed on 20 July 2026, about 60 days later. The records list a US approval dated 4 September 2026 (NDA220359). The FDA classes the product as a new molecular entity, formulated as a tablet.

The EU indication covers adults with ER-positive, HER2-negative, locally advanced or metastatic breast cancer. Etcamah is given in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib). Use is limited to patients in whom an ESR1 mutation has been detected and whose disease has not progressed during first-line endocrine therapy combined with a CDK4/6 inhibitor.

The indication is therefore defined by a biomarker and by a specific point in the treatment pathway. The label points to sections 4.2 and 5.1 of the product information for biomarker-based patient selection. The records do not give the content of those sections.

Regulatory pathway and designations

The records show a standard sequence: CHMP positive opinion, then an EC decision granting marketing authorisation to AstraZeneca AB. The EC decision normally follows the CHMP opinion and legally authorises marketing across all EU Member States. The records do not state which procedure type was used (for example standard or accelerated assessment, or any conditional or exceptional circumstances authorisation). They also do not mention orphan status or PRIME. I therefore make no claims on those points.

The only designation listed is additional monitoring. In the EU this is usually applied to products containing a new active substance, among other criteria. The records do not give the specific reason it applies here.

In the US, the records show an FDA approval as a new molecular entity under NDA220359. They give no information on review designations, such as priority review or breakthrough status, or on the label wording. A direct comparison of the US and EU indications is not possible from this data.

Safety and pharmacovigilance

The records contain no safety data. They include no adverse-event profile, contraindications, warnings, risk management plan details or post-authorisation safety commitments, and I do not infer any.

The additional monitoring status is the one pharmacovigilance-relevant fact. Such products carry a black inverted triangle in the product information and patient leaflet, along with a standard statement encouraging reporting of suspected adverse reactions. The status is a transparency and reporting measure. It does not by itself indicate a specific safety concern.

The product is used with a CDK4/6 inhibitor, so reporting of adverse reactions in practice will involve a combination regimen. Attributing events to individual components will matter for signal detection. The records do not say how the label addresses this.

What to watch

The records do not include any scheduled future events. Points to follow up in the primary documents are the EPAR and the product information, especially sections 4.2 and 5.1, for the test requirements and the evidence behind the biomarker-defined population. The US prescribing information should also be reviewed against the EU wording.

On the practical side, the ESR1 mutation requirement makes access depend on testing. Testing logistics, timing relative to first-line therapy, and national reimbursement and HTA decisions will shape uptake across Member States. The records contain no information on any of these.

From a pharmacovigilance standpoint, watch for the first periodic safety reporting under the additional monitoring framework. Any post-authorisation obligations should be checked in the EPAR, since none are given in the records.